Record number:
75
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for choriocarcinoma (Council of Europe, 2022):
Due to the high transmission and mortality rates, it is considered an unacceptable risk for organ donation in any stage of disease. History of choriocarcinoma: Due to the reported high transmission and mortality rates, it is considered to be associated with a high or unacceptable risk for transmission through organ donation, depending on the recurrence-free period prior to donor death.
Time to detection:
1 month
Alerting signals, symptoms, evidence of occurrence:
Increased Human Chorionic Gonadotropin (hCG) levels.
Demonstration of imputability or root cause:
Condition known in the donor. She was a 26-year-old pregnant woman who died from a cerebral hemorrhage initially attributed to a vascular malformation. Post-mortem histological examination demonstrated the presence of a placental choriocarcinoma three weeks after donation. More than one recipient affected from the same donor. The kidney recipient developed significantly elevated beta-HCG and underwent transplantectomy and chemotherapy. Histologic evidence of tumor was never documented, and tumor was not found, in this recipient. Tumor did develop in other recipients from this donor together with elevated HCG.
Imputability grade:
2 Probable
Groups audience:
Keywords:
Suggest new keywords:
Neoplasia
Deceased donor
Kidney transplant
Germ cell, sex cord and related tumors
Chemotherapy
Transplantectomy
Patient survival
Suggest references:
AAA
Expert comments for publication:
Allograft kidney removed 5 days after detection of elevated beta-HCG; retrospective serum assay showed it continued to rise but decreased eventually down to normal levels after transplantectomy (no tumor found in explanted allograft). Patient also received chemotherapy and was alive at 1 year without tumor at time of report.